NIH renews $7.5 million grant for eosinophilic gastrointestinal disorder research
Click Here to Manage Email Alerts
Cincinnati Children’s Hospital Medical Center has received a 5-year, $7.57 million grant renewal from the NIH to continue leading the Consortium of Eosinophilic Gastrointestinal Disease Researchers, a consortium of organizations across the United States that is conducting research into eosinophilic gastrointestinal disorders, according to a press release.
“These are painful, chronic diseases that make it difficult and sometimes impossible for individuals to eat many or all foods,” Marc Rothenberg, MD, PhD, director of the Cincinnati Center for Eosinophilic Disorders at Cincinnati Children’s and principal investigator on the grant, said in the release. “I look forward to continuing to advance the understanding and better treatment of these diseases by collaborating with outstanding researchers, patients and patient advocacy groups, as well as training the next generation of clinicians and researchers who will be experts in these diseases.”
The funding, according to the release, will continue to expand research and develop clinical expertise, train clinical investigators, pilot clinical research projects, and provide access to information related to eosinophilic disorders for basic and clinical researchers, physicians, patients and the lay public.
The consortium is also expected to work with a number of strong patient advocacy groups, including the American Partnership for Eosinophilic Disorders, the Campaign Urging Research for Eosinophilic Disease, and the Eosinophilic Family Coalition.
“Collaborative research is critical for progress in understanding and treating these rare diseases,” Glenn Furuta, MD, director of the Gastrointestinal Eosinophilic Diseases Program at Children’s Hospital Colorado and professor of pediatrics at the University of Colorado School of Medicine, said in the release. “Much has been accomplished with the support of patients and patient advocacy groups, our professional networks, and clinicians and researchers from around the globe. These conditions are a global health concern, and we look forward to continuing our work with everyone to improve the patient’s lives. We are so fortunate to continue these collaborations through this consortium and the stellar infrastructure and processes of the Rare Disease Research Network.”